Managing bites from humans and other mammals

Drug and Therapeutics Bulletin

Volumn 42, Issue 9, 2004, Pages 67-71

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIINFECTIVE AGENT; DIPHTHERIA VACCINE; DOXYCYCLINE; ERYTHROMYCIN; HEPATITIS B VACCINE; HYDROGEN PEROXIDE; IMMUNOGLOBULIN; PENICILLIN G; TETANUS TOXOID;

ARTICLE; BACTERIAL ARTHRITIS; BACTERIUM CONTAMINATION; BACTERIUM CULTURE; BACTEROIDES; BITE; BONE RADIOGRAPHY; CAPNOCYTOPHAGA; CAT; CLINICAL FEATURE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC PROCEDURE; DOG BITE; ELECTROENCEPHALOGRAM; EMERGENCY WARD; ENCEPHALITIS; FOLLOW UP; FUSOBACTERIUM; HAEMOPHILUS; HEPATITIS; HERPES; HERPES VIRUS; HOSPITAL ADMISSION; HUMAN; LEARNING DISORDER; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOMYELITIS; PASTEURELLA; PATIENT CARE; PATIENT REFERRAL; PHYSICAL EXAMINATION; PNEUMONIA; PREVALENCE; PRIMARY MEDICAL CARE; RABIES; RODENT; SEPSIS; SQUIRREL; STAPHYLOCOCCUS; STREPTOCOCCUS; TETANUS; TETANUS PROPHYLAXIS; TISSUE INJURY; UNITED KINGDOM; VIOLENCE; VIRUS TRANSMISSION; WOUND CARE; WOUND CLOSURE; WOUND INFECTION;

EID: 10244267667     PISSN: 00126543     EISSN: None     Source Type: Journal    
DOI: 10.1136/dtb.2004.42967     Document Type: Article

References (48)

1. Morgan M. The bacteriology and clinical aspects of bites. CPD Infection 2003; 4: 44-8.
2. Goldstein EJ. Bites. In: Mandell GL et al (Eds). Principles and Practice of Infectious Diseases. Fifth edition. Philadelphia: Churchill Livingstone, 2000.
3. Le Moal G et al. Meningitis due to Capnocytophaga canimorsus after receipt of a dog bite: case report and review of the literature. Clin Infect Dis 2003; 36: e42-6.
4. Goldstein EJ. Bite wounds and infection. Clin Infect Dis 1992; 14: 633-40.
5. Al Fallouji M. Traumatic love bites. Br J Surg 1990; 77: 100-1.
6. Talan DA et al. Clinical presentation and bacteriologic analysis of infected human bites in patients presenting to emergency departments. Clin Infect Dis 2003; 37: 1481-9.
7. Rest JG, Goldstein EJ. Management of human and animal bite wounds. Emerg Med Clin North Am 1985; 3: 117-26.
8. Brook I. Microbiology and management of human and animal bite wound infections. Prim Care Clin Office Pract 2003; 30: 25-39.
9. Chuinard RG, D'Ambrosia RD. Human bite infections of the hand. J Bone Joint Surg Am 1977; 59: 416-8.
10. Callaham ML. Treatment of common dog bites: infection risk factors.JACEP 1978; 7: 83-7.
11. Goldstein EJ et al. Role of anaerobic bacteria in bite-wound infections. Rev Infect Dis 1984; 6 (suppl 1): S177-83.
12. Prodigy guidance. Bites - human and animal (Last revised July 2004) [online]. Available from: http://www.prodigy.nhs.uk/guidance.asp?gt=Bites-human and animal [Accessed 16 August 2004].
13. Figueiredo JF et al. Transmission of hepatitis C virus but not human immunodeficiency virus type 1 by a human bite. Clin Infect Dis 1994; 19: 546-7.
14. Tereskerz PM et al. Risk of HIV-1 infection after human bites. Lancet 1996; 348: 1512.
15. Tsoukas CM et al. Lack of transmission of HIV through human bites and scratches. J Acquir Immune Defic Syndr 1988; 1: 505-7.
16. Weiss HB et al. Incidence of dog bite injuries treated in emergency departments. JAMA 1998; 279: 51-3.
17. Rohrich RJ. Man's best friend revisited: who's watching the children? Plastic and Reconstruct Surg 1999; 103: 2067-8.
18. Hicklin H et al. Dysgonic fermenter 2 septicemia. Rev Infect Dis 1987; 9: 884-90.
19. Job L et al. Dysgonic fermenter-2: A clinico-epidemiologic review. J Emerg Med 1989; 7: 185-92.
20. Talan DA et al. Bacteriologic analysis of infected dog and cat bites. N Engl J Med 1999; 340: 85-92.
21. Medeiros I, Saconato H. Antibiotic prophylaxis for mammalian bites (Cochrane review). In: The Cochrane Library, Issue 3, 2004. [Date of most recent substantive amendment: 11 February 2001].
22. Morgan MS. Tiger bites. J R Soc Med 1999; 92: 545.
23. Kravetz JD, Federman DG. Cat-associated zoonoses. Arch Intern Med 2002; 162: 1945-52.
24. Citron DM et al. Frequency of isolation of Porphyromonas species from infected dog and cat bite wounds in humans and their characterization by biochemical tests and arbitrarily primed-polymerase chain reaction fingerprinting. Clin Infect Dis 1996; 23 (suppl 1): S78-82.
25. Kaplan S et al. Cat-scratch disease in children - Texas, September 2000-August 2001. MMWR Morb Mortal Wkly Rep 2002; 51: 212-4.
26. Williams A et al. Cat scratch disease. BMJ 2002; 324: 1199-200.
27. Murakami K et al. Cat scratch disease: analysis of 130 seropositive cases. J Infect Chemother 2002; 8: 349-52.
28. Lion C et al. Pasteurella "SP" group infection after a guineapig bite. Lancet 1995; 346: 901-2.
29. Wyatt JP. Squirrel bites. BMJ 1994; 309: 1694.
30. Lewin MR et al. Seal finger. Lancet 2004; 364: 448.
31. Goldstein EJ et al. Simian bites and bacterial infection. Clin Infect Dis 1995; 20: 1551-2.
32. Holmes GP et al. Guidelines for the prevention and treatment of B-virus infections in exposed persons. Clin Infect Dis 1995; 20: 421-39.
33. Joint Formulary Committee. British National Formulary. Edition 47. London: Royal Pharmaceutical Society of Great Britain and British Medical Association, March 2004.
34. Mann RJ et al. Human bites of the hand: twenty years of experience. J Hand Surg 1977; 2: 97-104.
35. Stucker FJ et al. Management of animal and human bites in the head and neck. Arch Otolaryngol Head Neck Surg 1990; 116: 789-93.
36. Chief Medical Officer et al. Update on immunisation issues [PL/CMO/2002/4, PL/CNO/2002/4, PL/CPHO/2002/2]. Department of Health, August 2004.
37. Cummings P. Antibiotics to prevent infection in patients with dog bite wounds: a meta-analysis of randomized trials. Ann Emerg Med 1994; 23: 535-40.
38. Zubowicz VN, Gravier M. Management of early human bites of the hand: A prospective randomized study. Plast Reconstr Surg 1991; 88: 111-4.
39. Elenbaas RM et al. Evaluation of prophylactic oxacillin in cat bite wounds. Ann Emerg Med 1984; 13: 155-7.
40. Correira K. Managing dog, cat, and human bite wounds. JAAPA 2003; 16: 28-37.
41. Augmentin tablets 375mg/625mg, dispersible tablets 375mg, augmentin 250/62 and 125/31 SF suspension. Summary of product characteristics, UK. GlaxoSmithKline UK, June 2002.
42. Augmentin reconsidered. DTB 1996; 34: 76-8.
43. PHLS Hepatitis Subcommittee. Exposure to hepatitis B virus: guidance on post-exposure prophylaxis. Commun Dis Rep CDR Rev 1992; 2: R97-101.
44. Department of Health. HIV post-exposure prophylaxis: guidance from the UK Chief Medical Officers' Expert Advisory Group on AIDS, February 2004 [online]. Available from: http://www.advisorybodies.doh.gov.uk/eaga/prophylaxisguidancefeb04.pdf [Accessed 16 August 2004].
45. Department of Health. Immunisation against infectious disease, 1996 [online]. Available from: http://www.dh.gov.uk/assetRoot/04/07/29/84/04072984.pdf [Accessed 16 August 2004].
46. Merchant RC et al. Emergency department blood or body fluid exposure evaluations and HIV postexposure prophylaxis usage. Acad Emerg Med 2003; 10: 1345-53.
47. Department of Health. Memorandum on rabies prevention and control, Febuary 2000 [online]. Available from http://www/dh.gov.uk/assetRoot/04/08/06/57/0408065.pdf [Accessed 16 August 2004].
48. Nathwani D et al. Fatal human rabies caused by European bat Lyssavirus type 2a infection in Scotland. Clin Infect Dis 2003; 37: 598-601.